Genetic Technologies Financials
| GTG Stock | 0.04 0.00 0.00% |
Operating Margin (1.13) | Profit Margin (1.24) | Return On Equity (1.85) |
Genetic | Select Account or Indicator |
Understanding current and past Genetic Technologies Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Genetic Technologies' financial statements are interrelated, with each one affecting the others. For example, an increase in Genetic Technologies' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Genetic Technologies' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genetic Technologies. Check Genetic Technologies' Beneish M Score to see the likelihood of Genetic Technologies' management manipulating its earnings.
Genetic Technologies Stock Summary
Genetic Technologies competes with Coronado Global. Genetic Technologies is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | Canada |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU000000GTG7 |
| Business Address | 321 Chapel Street, |
| Sector | Life Sciences Tools & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | genetype.com |
| Phone | 61 3 8412 7000 |
You should never invest in Genetic Technologies without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Genetic Stock, because this is throwing your money away. Analyzing the key information contained in Genetic Technologies' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Genetic Technologies Key Financial Ratios
Genetic Technologies' financial ratios allow both analysts and investors to convert raw data from Genetic Technologies' financial statements into concise, actionable information that can be used to evaluate the performance of Genetic Technologies over time and compare it to other companies across industries.| Revenue | 7.66 M | ||||
| Gross Profit | 6.01 M | ||||
| EBITDA | (11.43 M) | ||||
| Net Income | (12.02 M) | ||||
| Total Asset | 6.19 M |
Genetic Technologies Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 15.6M | 23.0M | 20.8M | 14.9M | 6.2M | 5.9M | |
| Other Current Liab | 1.0M | 955.5K | 1.6M | 1.3M | 1.1M | 940.6K | |
| Net Debt | (13.7M) | (20.7M) | (11.1M) | (7.3M) | (145.4K) | (152.7K) | |
| Retained Earnings | (136.0M) | (143.1M) | (150.2M) | (156.7M) | (166.4M) | (158.1M) | |
| Accounts Payable | 350.2K | 269.7K | 1.2M | 838.0K | 1.5M | 851.7K | |
| Cash | 14.2M | 20.9M | 11.7M | 7.9M | 1.0M | 969.6K | |
| Net Receivables | 38.9K | 1.1M | 2.4M | 191.9K | 2.1M | 2.2M | |
| Inventory | 91.4K | 76.9K | 398.2K | 325.9K | 206.5K | 196.1K | |
| Total Liab | 1.6M | 1.4M | 4.4M | 3.7M | 4.4M | 2.3M | |
| Total Current Assets | 15.2M | 22.2M | 14.7M | 10.5M | 3.7M | 3.5M | |
| Common Stock | 140.1M | 153.6M | 155.1M | 161.3M | 163.8M | 99.3M | |
| Other Current Assets | 846.3K | 182.6K | 18.2K | 2.1M | 341.7K | 390.1K | |
| Other Liab | 979.2K | 8.9K | 170.5K | 152.3K | 175.2K | 133.1K | |
| Net Tangible Assets | 13.0M | 21.5M | 11.3M | 7.5M | 8.7M | 11.1M | |
| Long Term Debt Total | 240.9K | 24.4K | 388.4K | 229.3K | 263.7K | 138.8K | |
| Net Invested Capital | 13.1M | 21.5M | 16.4M | 11.2M | 2.5M | 2.4M | |
| Net Working Capital | 13.8M | 20.8M | 10.9M | 7.2M | (500.1K) | (475.1K) |
Genetic Technologies Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 14.8K | 14.0K | 15.2K | 29.5K | 51.6K | 83.6K | |
| Total Revenue | 9.9K | 120.6K | 6.8M | 10.3M | 7.7M | 5.3M | |
| Gross Profit | (241.6K) | (240.5K) | 6.5M | 6.0M | 3.9M | 3.8M | |
| Operating Income | (6.1M) | (7.4M) | (7.5M) | (10.4M) | (6.5M) | (6.9M) | |
| Ebit | (6.1M) | (7.5M) | (7.8M) | (11.9M) | (12.0M) | (11.4M) | |
| Ebitda | (6.0M) | (7.1M) | (7.2M) | (11.2M) | (11.4M) | (10.9M) | |
| Cost Of Revenue | 251.5K | 361.0K | 321.2K | 4.3M | 3.8M | 3.9M | |
| Income Before Tax | (6.1M) | (7.1M) | (7.2M) | (11.9M) | (12.0M) | (11.4M) | |
| Net Income | (6.1M) | (7.1M) | (7.1M) | (11.8M) | (12.0M) | (11.4M) | |
| Income Tax Expense | 140.0K | (135.4K) | (32.1K) | 158.3K | (2.0M) | (1.9M) | |
| Research Development | 2.5M | 3.1M | 705.5K | 1.3M | 752.8K | 715.1K | |
| Net Interest Income | (14.8K) | 48.3K | (275.8K) | (235.9K) | (323.7K) | (307.6K) | |
| Interest Income | 14.8K | 62.4K | 36.3K | 220.2K | 119.5K | 72.6K |
Genetic Technologies Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (59.5K) | 14.5K | (351.4K) | 72.3K | 119.4K | 125.4K | |
| Change In Cash | 12.1M | 6.7M | 21.4M | (3.9M) | (6.8M) | (6.5M) | |
| Free Cash Flow | (5.8M) | (6.9M) | (5.8M) | (9.7M) | (9.7M) | (9.2M) | |
| Depreciation | 265.9K | 478.2K | 578.7K | 676.6K | 534.9K | 508.1K | |
| Other Non Cash Items | 316.7K | 303.5K | 892.9K | 1.4M | 1.4M | 1.5M | |
| Capital Expenditures | 38.1K | 642K | 96.8K | 17.6K | 33.0K | 31.3K | |
| Net Income | (6.3M) | (7.1M) | (7.1M) | (11.8M) | (12.0M) | (11.4M) | |
| End Period Cash Flow | 14.2M | 20.9M | 11.7M | 7.9M | 1.0M | 969.6K | |
| Change To Netincome | (606.5K) | 732.8K | 766.1K | 1.7M | 2.0M | 2.1M |
Genetic Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Genetic Technologies's current stock value. Our valuation model uses many indicators to compare Genetic Technologies value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Genetic Technologies competition to find correlations between indicators driving Genetic Technologies's intrinsic value. More Info.Genetic Technologies is one of the top stocks in return on equity category among its peers. It also is one of the top stocks in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Genetic Technologies' earnings, one of the primary drivers of an investment's value.Genetic Technologies Systematic Risk
Genetic Technologies' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Genetic Technologies volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Genetic Technologies correlated with the market. If Beta is less than 0 Genetic Technologies generally moves in the opposite direction as compared to the market. If Genetic Technologies Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Genetic Technologies is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Genetic Technologies is generally in the same direction as the market. If Beta > 1 Genetic Technologies moves generally in the same direction as, but more than the movement of the benchmark.
Genetic Technologies Total Assets Over Time
Genetic Technologies Thematic Clasifications
Genetic Technologies is part of IT investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains
This theme covers Information technology and IT services. Information Technology (IT) companies and IT service providers across different domains. Get More Thematic Ideas
| IT | View |
Genetic Technologies November 30, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Genetic Technologies help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Genetic Technologies. We use our internally-developed statistical techniques to arrive at the intrinsic value of Genetic Technologies based on widely used predictive technical indicators. In general, we focus on analyzing Genetic Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Genetic Technologies's daily price indicators and compare them against related drivers.
| Downside Deviation | 6.59 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 25.97 | |||
| Value At Risk | (7.14) | |||
| Potential Upside | 8.33 |
Additional Tools for Genetic Stock Analysis
When running Genetic Technologies' price analysis, check to measure Genetic Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genetic Technologies is operating at the current time. Most of Genetic Technologies' value examination focuses on studying past and present price action to predict the probability of Genetic Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genetic Technologies' price. Additionally, you may evaluate how the addition of Genetic Technologies to your portfolios can decrease your overall portfolio volatility.